Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kiora Pharmaceuticals (KPRX) Net Income (2016 - 2025)

Kiora Pharmaceuticals (KPRX) has disclosed Net Income for 11 consecutive years, with $26805.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Income rose 100.79% year-over-year to $26805.0, compared with a TTM value of -$8.6 million through Sep 2025, down 273.44%, and an annual FY2024 reading of $3.6 million, up 128.45% over the prior year.
  • Net Income was $26805.0 for Q3 2025 at Kiora Pharmaceuticals, up from -$2.2 million in the prior quarter.
  • Across five years, Net Income topped out at $13.5 million in Q1 2024 and bottomed at -$14.4 million in Q4 2021.
  • Average Net Income over 5 years is -$2.1 million, with a median of -$2.2 million recorded in 2024.
  • The sharpest move saw Net Income plummeted 5345.16% in 2022, then surged 801.91% in 2024.
  • Year by year, Net Income stood at -$14.4 million in 2021, then surged by 74.27% to -$3.7 million in 2022, then grew by 22.42% to -$2.9 million in 2023, then plummeted by 48.23% to -$4.3 million in 2024, then soared by 100.63% to $26805.0 in 2025.
  • Business Quant data shows Net Income for KPRX at $26805.0 in Q3 2025, -$2.2 million in Q2 2025, and -$2.2 million in Q1 2025.